4-Ethyl-cyclohexanol-acetat | 500283-40-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-Ethyl-cyclohexanol-acetat
• 英文别名: (4-Ethylcyclohexyl) acetate
• CAS: 500283-40-9
• 化学式: C₁₀H₁₈O₂
• 分子量: 170.252
• InChiKey: XJWLSIUGKJSAFZ-UHFFFAOYSA-N

物化性质

• 沸点：
  209.8±8.0 °C(Predicted)
• 密度：
  0.94±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-Ethyl-cyclohexanol-acetat 生成 4-ethylcyclohexene
  参考文献：
  名称：

  The addition of trichlorosilane to cyclic olefins

  摘要：

  DOI：

  10.1021/ja01009a033
• 作为产物：
  描述：

  4-乙基苯酚 在 镍 氢气 作用下， 以 四氯化碳 为溶剂， 生成 4-Ethyl-cyclohexanol-acetat
  参考文献：
  名称：

  The addition of trichlorosilane to cyclic olefins

  摘要：

  DOI：

  10.1021/ja01009a033

文献信息

• [EN] NRF2 REGULATORS<br/>[FR] RÉGULATEURS DE NRF2
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2016202253A1

  公开（公告）日：2016-12-22

  Provided are aryl analogs，pharmaceutical compositions containing them and their use as NRF2 regulators.

  提供芳基类似物，含有它们的药物组合物以及它们作为NRF2调节剂的用途。
• NRF2 REGULATORS
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：EP3307739A1

  公开（公告）日：2018-04-18
• METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS
  申请人：NOVARTIS AG

  公开号：US20140134262A1

  公开（公告）日：2014-05-15

  The present invention provides a compound of Formula I: for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride level; wherein R 1 , X 1 , R 7 , R 5 , C, L and p are defined herein. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride levels.
• NANOPARTICLE, PROCESS, LIQUID CRYSTAL DISPLAY PANEL AND DISPLAY DEVICE FOR INDUCING LIQUID CRYSTAL ALIGNMENT
  申请人：BEIJING BOE OPTOELECTRONICS TECHNOLOGY CO., LTD.

  公开号：US20140319420A1

  公开（公告）日：2014-10-30

  The invention provides a nanoparticle, a process, a liquid crystal display panel and a display device for inducing liquid crystal alignment in an advanced super dimension switch mode. The nanoparticle is a silicon dioxide nanoparticle modified using the organic silicon compound of Formula (1), wherein R can be the same or different and is —H or —OC 2 H 5 ; M contains rigid groups such as benzene ring, biphenyl, and/or cyclohexane. In the invention, the organic silicon compounds, which share similar structures with the nematic liquid crystal molecules in the ADS mode, are employed for modifying the silicon dioxide nanoparticles, facilitating the even dispersion of the modified silicon dioxide nanoparticles in liquid crystals; and the organic silicon compound contains rigid groups that can effectively induce the directional alignment of the liquid crystals, thereby helping improve the display effect of the ADS mode liquid crystal display panel. Moreover, it can help reducing the driving voltage of the liquid crystal display so as to decrease the energy consumption.
• US9206356B2
  申请人：——

  公开号：US9206356B2

  公开（公告）日：2015-12-08